ICTRP Search Portal

Main

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.

Register:	JPRN
Last refreshed on:	17 October 2023
Main ID:	JPRN-UMIN000035602
Date of registration:	21/01/2019
Prospective Registration:	No
Primary sponsor:	Juntendo University Koshigaya Hospital
Public title:	Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease
Scientific title:	Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease - Hydrogen gas inhalation randomized double blinded trial for Parkinson's disease
Date of first enrolment:	2019/01/11
Target sample size:	20
Recruitment status:	Complete: follow-up complete
URL:	https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039217
Study type:	Interventional
Study design:	Parallel Randomized
Phase:	Not selected

Countries of recruitment
Japan

Contacts

Name:	Asako Yoritaka
Address:	Fukuroyama560, Koshigaya-shi, Saitama Japan
Telephone:	0489750321
Email:	ayori@juntendo.ac.jp
Affiliation:	Juntendo University Koshigaya Hospital Neurology

Name:	Asako Yoritaka
Address:	Fukuroyama 560, Koshigaya-shi, Saitama Japan
Telephone:	0489750321
Email:	ayori@juntendo.ac.jp
Affiliation:	Juntendo University Koshigaya Hospital Neurology

Key inclusion & exclusion criteria

Inclusion criteria:
Exclusion criteria: Parkinsonism except Parkinson's disease modified Hoehn and Yahr stage 4~5 with dementia with lung disease with malignant tumor

Age minimum: 40years-old
Age maximum: 80years-old
Gender: Male and Female

Health Condition(s) or Problem(s) studied

Parkinson's disease

Intervention(s)

hydrogen gas16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation
placebo gas 16 weeks inhalation two times of the inhalation for 60 minutes per day 8 weeks obsebation after the inhalation

Primary Outcome(s)

The change of MDS-UPDRS from the baseline to 16th week between hydrogen gas and placebo gas

Secondary Outcome(s)

The change of parts of MDS-UPDRS PDQ-39 18-OHdG N1,N8-diacetylspermidine from the baseline to 16th week between hydrogen gas and placebo gas

Secondary ID(s)

Source(s) of Monetary Support

MiZ company

Secondary Sponsor(s)

Ethics review

Status: YES
Approval date: 12/11/2018
Contact:

Results

Results available:	Yes
Date Posted:
Date Completed:	31/03/2020
URL:

Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.